Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

JETREA® Selected for Single Technology Appraisal (STA) by the UK's National Institute for Health and Clinical Excellence (NICE



 JETREA® Selected for Single Technology Appraisal (STA) by the UK's National
             Institute for Health and Clinical Excellence (NICE)

  PR Newswire

  LEUVEN, Belgium, November 27, 2012

LEUVEN, Belgium, November 27, 2012 /PRNewswire/ --

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical
company focused on developing and commercializing innovative ophthalmic
medicines, today announces that JETREA ^® (ocriplasmin) has been selected to
receive a Single Technology Appraisal (STA) from the UK's National Institute
for Health and Clinical Excellence (NICE). The outcome of the STA, in the form
of NICE guidance, is expected later in 2013, following the launch of JETREA ^®
in the UK.

The JETREA ^® European Marketing Authorisation Application is currently under
review by the European Medicines Agency. A decision on European approval is
expected in the first half of 2013. JETREA ^® was recently approved by the
U.S. Food and Drugs Administration for the treatment of symptomatic
Vitreomacular Adhesion (VMA). In March 2012, ThromboGenics signed a strategic
partnership with Alcon (Novartis) for the commercialization of ocriplasmin
outside the United States

The NICE STA process is designed to provide recommendations on the use of new
medicines in the National Health Service (NHS). The STA is specifically
designed to appraise a single product with a single indication, and enables
NICE to produce guidance soon after the technology is introduced in the UK.
During the appraisal process, NICE seeks evidence from several sources.
ThromboGenics and its partner Alcon, will submit the principal evidence for
the JETREA ^® STA shortly. This submission will be assessed by an Evidence
Review Group (ERG), an external independent academic organization, which will
produce a review of the evidence submission. The STA also relies on
information and evidence from clinical consultants, and NHS commissioning
authorities as well as patient groups.

Dr Patrik De Haes, CEO at ThromboGenics , said: "We are delighted that the  
UK   Department of Health has asked NICE to appraise   JETREA ^®  
(ocriplasmin)   for the treatment of vitreomacular traction . We strongly
believe that JETREA ^®   has the potential to dramatically change the
treatment paradigm in the   UK   for this progressive sight threatening
condition".   We plan to submit, along with our partner Alcon, our dossier for
the STA shortly and look forward to working with NICE and all parties involved
in the appraisal process. "

About   JETREA ^®  ( ocriplasmin)

JETREA ^® (ocriplasmin) is a truncated form of human plasmin for the treatment
of symptomatic VMA. JETREA ^® is a selective proteolytic enzyme that cleaves
fibronectin, laminin and collagen, three major components of the vitreoretinal
interface that play an important role in vitreomacular adhesion.

JETREA ^® has been evaluated in two multi-center, randomized, double-masked
Phase III trials conducted in the U.S. and Europe involving 652 patients with
vitreomacular adhesion. Both studies met the primary endpoint of resolution of
VMA at day 28.

JETREA ^® 's Phase III program found that 26.5% of patients treated with
ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving
placebo (p<0.01). The Phase III program also showed that JETREA ^® was
generally well tolerated with most adverse events being transient and mild in
severity.

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing
and commercializing innovative ophthalmic medicines. The Company's lead
product, JETREA ^® (ocriplasmin), has been approved by the FDA for the
treatment of symptomatic VMA. The Marketing Authorisation Application (MAA)
for ocriplasmin is under review in Europe.

In March 2012, ThromboGenics signed a strategic partnership with Alcon
(Novartis) for the commercialization of JETREA ^® outside the United States.
Under this agreement, ThromboGenics could receive up to a total of €375
million in up-front and milestone payments. It will receive significant
royalties from Alcon's net sales of JETREA ^® . ThromboGenics and Alcon intend
to share the costs equally of developing JETREA ^® for a number of new
vitreoretinal indications.

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor),
formerly referred to as TB-403, for the treatment of ophthalmic indications.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin,
NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext
Brussels exchange under the symbol THR. More information is available at
http://www.thrombogenics.com .

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained
in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction.   No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.

For further information please contact: ThromboGenics Wouter Piepers, Global
Head of Corporate Communications +32-16-75-13-10 / +32-478-33-56-32
wouter.piepers@thrombogenics.com Dr. Patrik De Haes, CEO +32-16-75-13-10
Patrik.dehaes@thrombogenics.com Chris Buyse, CFO +32-16-75-13-10
Chris.buyse@thrombogenics.com Citigate Dewe Rogerson David Dible/ Nina
Enegren/ Sita Shah Tel: +44-20-7638-9571 sita.shah@citigatedr.co.uk The Trout
Group (US investor relations) Todd James/ Simon Harnest Tel: +1-646-378-2926
tjames@troutgroup.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement